Exelixis
EXEL
#1649
Rank
C$14.66 B
Marketcap
$52.41
Share price
5.02%
Change (1 day)
87.41%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total liabilities

Total liabilities on the balance sheet as of December 2024 : C$1.00 Billion

According to Exelixis's latest financial reports the company's total liabilities are C$1.00 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Exelixis - Total liabilities on balance sheet (from 2001 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31C$0.89 B13.74%
2022-12-31C$0.79 B53.05%
2021-12-31C$0.51 B57.01%
2020-12-31C$0.32 B26.24%
2019-12-31C$0.26 B42.01%
2018-12-31C$0.18 B-60.55%
2017-12-31C$0.46 B-31.58%
2016-12-31C$0.68 B3.69%
2015-12-31C$0.65 B29.1%
2014-12-31C$0.50 B9.28%
2013-12-31C$0.46 B10.17%
2012-12-31C$0.42 B37.18%
2011-12-31C$0.30 B-47.73%
2010-12-31C$0.58 B10.36%
2009-12-31C$0.53 B-4.15%
2008-12-31C$0.55 B70.87%
2007-12-31C$0.32 B-8.19%
2006-12-31C$0.35 B10.68%
2005-12-31C$0.32 B10.93%
2004-12-31C$0.28 B13.51%
2003-12-31C$0.25 B-1.2%
2002-12-31C$0.25 B47.9%
2001-12-31C$0.17 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
C$84.88 B 8,384.05%๐Ÿ‡ฌ๐Ÿ‡ง UK
C$86.53 B 8,548.87%๐Ÿ‡ซ๐Ÿ‡ท France
C$103.78 B 10,272.90%๐Ÿ‡บ๐Ÿ‡ธ USA
C$108.40 B 10,733.89%๐Ÿ‡บ๐Ÿ‡ธ USA
C$118.55 B 11,748.98%๐Ÿ‡บ๐Ÿ‡ธ USA
C$154.48 B 15,339.38%๐Ÿ‡บ๐Ÿ‡ธ USA
C$180.51 B 17,941.27%๐Ÿ‡บ๐Ÿ‡ธ USA
C$72.83 M-92.72%๐Ÿ‡บ๐Ÿ‡ธ USA
C$0.10 B-89.71%๐Ÿ‡บ๐Ÿ‡ธ USA